ACLX Stock Price, Arcellx, Inc. Quote, Chart

Market Summary

USD53.51-1.66

Market Closed

-3.01%

ACLX Alerts

5 major insider sales recently.

ACLX Stock Price

View Fullscreen

ACLX RSI Chart

ACLX Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-41.21

Price/Sales (Trailing)

26.4

EV/EBITDA

-37.04

Price/Free Cashflow

15.65

ACLX Price/Sales (Trailing)

ACLX Profitability

EBT Margin

-63.48%

Return on Equity

-14.56%

Return on Assets

-8.57%

Free Cashflow Yield

6.39%

ACLX Fundamentals

ACLX Revenue

Revenue (TTM)

110.3M

ACLX Earnings

Earnings (TTM)

-70.7M

Earnings Growth (Yr)

150.89%

Earnings Growth (Qtr)

150.45%

Breaking Down ACLX Revenue

52 Week Range

30.7454.54

(Low)(High)

Last 7 days

-8.9%

Last 30 days

-21.9%

Last 90 days

0.6%

Trailing 12 Months

60.9%

How does ACLX drawdown profile look like?

ACLX Financial Health

Current Ratio

6.06

ACLX Investor Care

Shares Dilution (1Y)

11.02%

Diluted EPS (TTM)

-1.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	110.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Arcellx, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	elghandour rami	sold	-1,548,890	67.092	-23,086	see remarks
Mar 26, 2024	heery christopher	sold	-376,648	69.1097	-5,450	chief medical officer
Mar 26, 2024	heery christopher	acquired	34,226	6.28	5,450	chief medical officer
Mar 22, 2024	heery christopher	sold	-2,903,070	70.1817	-41,365	chief medical officer
Mar 22, 2024	heery christopher	acquired	125,600	6.28	20,000	chief medical officer
Mar 21, 2024	carroll jill	sold	-35,575,800	70.55	-504,263	-
Mar 18, 2024	gilson michelle	sold	-473,256	69.3415	-6,825	chief financial officer
Mar 15, 2024	ware olivia c	sold	-633,582	70.398	-9,000	-
Mar 15, 2024	ware olivia c	acquired	68,490	7.61	9,000	-
Feb 12, 2024	heery christopher	sold	-191,251	64.4595	-2,967	chief medical officer

Which funds bought or sold ACLX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-3.42	49,501	284,877	0.01%
Apr 12, 2024	High Net Worth Advisory Group LLC	added	14.29	167,900	556,400	0.17%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	534	2,643	-%
Apr 11, 2024	CONGRESS ASSET MANAGEMENT CO /MA	reduced	-7.31	224,732	1,615,510	0.01%
Apr 05, 2024	GAMMA Investing LLC	added	32.17	3,460	10,572	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	1,000	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	sold off	-100	-2,296,320	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.14	41,287,500	114,431,000	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-18.69	8,092,020	39,481,900	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	0.66	378,560	1,058,160	-%

Are Funds Buying or Selling ACLX?

Are funds buying ACLX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACLX

No. of Funds

ACLX Alerts

5 major insider sales recently.

Unveiling Arcellx, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	fmr llc	-	0	SC 13G/A
Mar 25, 2024	sr one capital management, llc	4.44%	2,346,630	SC 13D/A
Feb 14, 2024	paradigm biocapital advisors lp	7.0%	3,658,624	SC 13G/A
Feb 14, 2024	perceptive advisors llc	8.8%	4,544,809	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	5.0%	2,435,974	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 29, 2024	blackrock inc.	6.2%	3,018,538	SC 13G
Dec 28, 2023	gilead sciences, inc.	12.9%	6,720,803	SC 13G/A
Dec 18, 2023	sr one capital management, llc	6.46%	3,146,630	SC 13D/A
Jul 21, 2023	paradigm biocapital advisors lp	5.05%	2,422,700	SC 13G

Recent SEC filings of Arcellx, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 26, 2024	4	Insider Trading
Mar 25, 2024	SC 13D/A	13D - Major Acquisition
Mar 25, 2024	4	Insider Trading
Mar 22, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Arcellx, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-0.04%	-27.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.63%	-28.69%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	8.39%	-9.36%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.82%	-29.04%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-8.69%	-36.86%	-11.82	15.75	425.83%	18.94%
BBIO	4.4B	-	-8.20%	68.33%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-8.92%	-2.36%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.30%	-24.47%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-11.77%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.36%	-14.10%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-24.76%	-57.93%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-5.56%	294.36%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	-10.24%	-14.54%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	86.67%	92.16%	-0.25	2.14	-13.45%	66.37%

Arcellx, Inc. News

Latest updates

Arcellx, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1
Revenue	322.2%	63,148,000	14,957,000	14,302,000	17,912,000
Operating Expenses	-19.5%	48,149,000	59,819,000	43,862,000	48,369,000
S&GA Expenses	20.9%	19,365,500	16,012,000	15,535,000	15,437,000
R&D Expenses	-34.3%	28,783,500	43,807,000	28,327,000	32,932,000
EBITDA Margin	-Infinity%	-0.62	-	-	-
Income Taxes	10708.3%	636,500	-6,000	-282,000	300,000
Earnings Before Taxes	152.0%	20,466,000	-39,342,000	-24,136,000	-27,015,000
EBT Margin	-Infinity%	-0.63	-	-	-
Net Income	150.4%	19,844,000	-39,336,000	-23,854,000	-27,344,000
Net Income Margin	-Infinity%	-0.64	-	-	-
Free Cashflow	393.7%	52,955,000	-18,029,000	-29,843,000	181,062,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	34.3%	825	614	624	623	314	337	375	247	129	58.00
Current Assets	45.8%	716	491	558	571	267	290	325	224	113	49.00
Cash Equivalents	212.9%	395	126	304	275	64.00	57.00	165	127	31.00	47.00
Net PPE	13.1%	43.00	38.00	22.00	14.00	11.00	10.00	10.00	10.00	10.00	5.00
Liabilities	-2.4%	340	348	330	319	109	101	51.00	19.00	17.00	7.00
Current Liabilities	-31.7%	118	173	156	166	57.00	45.00	24.00	14.00	15.00	5.00
Shareholder's Equity	82.4%	485	266	294	304	205	236	324	228	-121	-
Retained Earnings	4.8%	-389	-409	-370	-346	-318	-279	-186	-156	-130	-65.14
Additional Paid-In Capital	29.4%	874	675	664	650	524	516	511	384	9.00	1.00
Shares Outstanding	7.4%	52.00	49.00	48.00	48.00	44.00	34.00	29.00	21.00	-	0.00
Float	-	-	-	1,300	-	-	-	453	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	676.6%	58.00	-10.10	-22.61	182	-27.52	-16.65	-22.55	-32.59	-21.55	-12.22	-10.96	-9.51	-
Share Based Compensation	0.0%	11.00	11.00	10.00	10.00	6.00	5.00	6.00	4.00	3.00	2.00	1.00	1.00	-
Cashflow From Investing	113.1%	21.00	-160	51.00	-66.77	34.00	-81.42	-59.23	-10.64	-17.66	-61.07	-0.18	-1.07	-
Cashflow From Financing	3880.1%	189	-4.99	0.00	95.00	1.00	-9.71	121	140	0.00	-0.47	37.00	82.00	-

ACLX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue from related party	$ 110,319
Operating expenses:
Research and development	133,849	$ 149,555
General and administrative	66,350	41,704
Total operating expenses	200,199	191,259
Loss from operations	(89,880)	(191,259)
Other income (expense):
Interest and other income (expense), net	23,695	4,300
Interest expense	(3,842)	(1,720)
Total other income, net	19,853	2,580
Loss before income taxes	(70,027)	(188,679)
Income tax (expense) benefit	(663)
Net loss	(70,690)	(188,679)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	768	(201)
Comprehensive loss	$ (69,922)	$ (188,880)
Net loss per share attributable to common stockholders - basic	$ (1.47)	$ (5.19)
Net loss per share attributable to common stockholders - diluted	$ (1.47)	$ (5.19)
Weighted-average common shares outstanding - basic	48,061,450	36,355,758
Weighted-average common shares outstanding - diluted	48,061,450	36,355,758

ACLX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets, Current [Abstract]
Cash and cash equivalents	$ 394,583	$ 64,179
Marketable securities	307,434	190,656
Restricted cash, current	1,903	0
Prepaid expenses and other current assets	12,443	12,028
Total current assets	716,363	266,863
Restricted cash, non-current	2,418	2,501
Marketable securities, non-current	27,168	0
Property and equipment, net	42,728	11,231
Operating lease right-of-use assets	27,099	28,659
Prepaid research and development expenses and other long-term assets	9,356	4,563
Total assets	825,132	313,817
Current liabilities:
Accounts payable	2,619	9,053
Accrued liabilities	18,302	11,679
Operating lease liabilities, current portion	7,501	2,901
Finance lease liabilities, current portion	39,283	33,060
Less: current portion	50,533
Total current liabilities	118,238	56,693
Operating lease liabilities, net of current portion	50,841	31,299
Finance lease liabilities, net of current portion		20,871
Noncurrent portion	170,673	0
Total liabilities	339,752	108,863
Commitments and Contingencies (Note 11)
Stockholders' equity
Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 52,280,077 shares issued and outstanding as of December 31, 2023; 1,000,000,000 shares authorized and 44,105,981 shares issued and outstanding as of December 31, 2022	52	44
Additional paid-in capital	874,261	523,921
Accumulated other comprehensive income (loss)	547	(221)
Accumulated Deficit	(389,480)	(318,790)
Total stockholders' equity	485,380	204,954
Total liabilities and stockholders' equity	$ 825,132	$ 313,817

About Arcellx, Inc.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

CEO	Mr. Rami Elghandour
WEBSITE	https://arcellx.com
INDUSTRY	Biotechnology
EMPLOYEES	98

Arcellx, Inc. Frequently Asked Questions

What is the ticker symbol for Arcellx, Inc.? What does ACLX stand for in stocks?

ACLX is the stock ticker symbol of Arcellx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcellx, Inc. (ACLX)?

As of Tue Apr 16 2024, market cap of Arcellx, Inc. is 2.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACLX stock?

You can check ACLX's fair value in chart for subscribers.

What is the fair value of ACLX stock?

You can check ACLX's fair value in chart for subscribers. The fair value of Arcellx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcellx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcellx, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACLX is over valued or under valued. Whether Arcellx, Inc. is cheap or expensive depends on the assumptions which impact Arcellx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACLX.

What is Arcellx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, ACLX's PE ratio (Price to Earnings) is -41.21 and Price to Sales (PS) ratio is 26.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACLX PE ratio will change depending on the future growth rate expectations of investors.